prostate, lung, colon, ovarian, and skin—using ribonucleic acid interference (RNAi). With this interference, also known as “gene silencing,” messenger RNA are destroyed from a virus before the infected cell turns those RNA into proteins that propagate the infection. PeptiMed is seeking financing to file an investigational new drug application with the FDA, according to the website.
—More funding news: Silatronix, a maker of silicon-based materials that can be used as electrolytes in batteries and other energy storage devices, raised $8 million from investors. Among the groups and individuals who participated in the equity financing round were Hitachi Chemical and Inabata, both of Japan. The materials Silatronix develops can function as electrolytes in lithium-ion batteries, which are used in everything from smartphones to electric vehicles.
—I spoke with Peter Pruessing of Inception Health, an investment group that’s part of Froedtert & the Medical College of Wisconsin, a health system concentrated in the southeastern part of the state. Inception will focus on providing funding to digital health startups that have developed quickly scalable technologies, Pruessing said. His organization came out of stealth mode last month when it announced it had invested an undisclosed amount in the Chicago-based Avia Innovator Network.
